The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
Johnson and Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and ...
California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback